{'fraction_non_alphanumeric': 0.0433996383363472, 'fraction_numerical': 0.0, 'mean_word_length': 5.925, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A multiplex model of combining gene‐based, protein‐based, and metabolite‐based with positive and negative markers in urine for the early diagnosis of prostate cancer

Multiplex urine‐based assay emerged outperforms single biomarker (e.g., prostate‐specific antigen, PSA) for predicting prostate cancer (CaP), whereas its combined mode has to be fully optimized. Our aim is to determine whether a strategy of combining gene‐based, protein‐based, metabolite‐based with positive, negative makers in urine could optimize a multiplex model for detecting CaP.